Jack W. Callicutt
2015
In 2015, Jack W. Callicutt earned a total compensation of $425.9K as Chief Financial Officer at Galectin Therapeutics, a 22% decrease compared to previous year.
Compensation breakdown
| Bonus | $69,120 |
|---|---|
| Option Awards | $72,377 |
| Salary | $240,000 |
| Other | $44,419 |
| Total | $425,916 |
Callicutt received $240K in salary, accounting for 56% of the total pay in 2015.
Callicutt also received $69.1K in bonus, $72.4K in option awards and $44.4K in other compensation.
Rankings
In 2015, Jack W. Callicutt's compensation ranked 11,386th out of 13,638 executives tracked by ExecPay. In other words, Callicutt earned more than 16.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 11,386 out of 13,638 | 17th |
Division Manufacturing | 4,361 out of 5,190 | 16th |
Major group Chemicals And Allied Products | 1,603 out of 1,854 | 14th |
Industry group Drugs | 1,323 out of 1,528 | 13th |
Industry Pharmaceutical Preparations | 1,027 out of 1,182 | 13th |
Source: SEC filing on November 7, 2017.
Callicutt's colleagues
We found three more compensation records of executives who worked with Jack W. Callicutt at Galectin Therapeutics in 2015.
News
Galectin Therapeutics CEO Joel Lewis' 2023 pay slips 1% to $964K
December 3, 2024
Galectin Therapeutics CEO Joel Lewis' 2022 pay slips 17% to $974K
October 6, 2023
Galectin Therapeutics CEO Joel Lewis' 2021 pay jumps 55% to $1.2M
October 17, 2022
Galectin Therapeutics CEO Harold Shlevin's 2019 pay falls 25% to $1.3M
October 19, 2020